Skip to main content
. Author manuscript; available in PMC: 2018 May 15.
Published in final edited form as: Clin Cancer Res. 2016 Oct 25;23(10):2516–2527. doi: 10.1158/1078-0432.CCR-16-1834

Figure 4.

Figure 4

5T4 is highly expressed in CSCs and MEDI0641 targets these cells in normal and low-attachment conditions. (A) Flow cytometry gating and graph depicting the expression of 5T4 in the CSC and non-CSC fractions in UM-SCC-11B and UM-SCC-22B cells. (B) Flow cytometry gating and graph depicting the percentage of ALDHhighCD44high cells in UM-SCC-11B and UM-SCC-22B cells following treatment with the IC50 values for each line (522 ng/mL or 686 ng/mL, respectively) of either IgG1-PBD control or MEDI0641. (C) Graph depicting the number of UM-SCC-22B orospheres per well over time after treatment with a 2-fold concentration gradient of MEDI0641 at 0.156, 0.312, 0.625, 1.25, 2.5, 5, and 10 μg/mL. IgG1-PBD control treatments represented by the solid black bars, were given at 10 μg/mL. Superimposed lines were generated from regression analyses of dose dependency at each time point. Representative images of orospheres after 3 days of treatment with either 10 μg/mL IgG1-PBD control or MEDI0641 at 40x and 100x magnifications.